Bio-Rad Laboratories, Inc. (BIO) stock
BIONYSELaboratory Analytical InstrumentsFiscal year ends December 31Also trades as BIO.B
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/3069% below fair value
$366.36−4.12 (-1.11%)
Close on Nov 13, 2026Market cap $9.92BP/E 9.8Yield –
Bio-Rad Laboratories total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Bio-Rad Laboratories's total debt was $803.10M at Sep 30, 2026. For fiscal 2025 it was $1.20B, up 0.1% from the year before. Over ten years it grew 10.7% a year on average. The highest annual figure on record is $1.48B in fiscal 2009.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.20B | +0.1% |
| FY2024 | Dec 31, 2024 | $1.20B | +0.1% |
| FY2023 | Dec 31, 2023 | $1.20B | +0.1% |
| FY2022 | Dec 31, 2022 | $1.20B | +11291.5% |
| FY2021 | Dec 31, 2021 | $10.51M | -14.2% |
| FY2020 | Dec 31, 2020 | $12.26M | -9.7% |
| FY2019 | Dec 31, 2019 | $13.58M | -96.9% |
| FY2018 | Dec 31, 2018 | $438.94M | +1.0% |
| FY2017 | Dec 31, 2017 | $434.58M | +0.1% |
| FY2016 | Dec 31, 2016 | $434.19M | +0.1% |
| FY2015 | Dec 31, 2015 | $433.88M | -0.4% |
| FY2014 | Dec 31, 2014 | $435.71M | -0.0% |
| FY2013 | Dec 31, 2013 | $435.82M | -40.5% |
| FY2012 | Dec 31, 2012 | $732.61M | +0.0% |
| FY2011 | Dec 31, 2011 | $732.30M | -24.1% |
| FY2010 | Dec 31, 2010 | $964.20M | -34.7% |
| FY2009 | Dec 31, 2009 | $1.48B | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $803.10M | -33.2% |
| Q2 FY2026 | Jun 30, 2026 | $803.00M | -33.1% |
| Q1 FY2026 | Mar 31, 2026 | $802.90M | -33.1% |
| Q4 FY2025 | Dec 31, 2025 | $1.20B | +0.1% |
| Q3 FY2025 | Sep 30, 2025 | $1.20B | +0.1% |
| Q2 FY2025 | Jun 30, 2025 | $1.20B | +0.1% |
| Q1 FY2025 | Mar 31, 2025 | $1.20B | +0.1% |
| Q4 FY2024 | Dec 31, 2024 | $1.20B | +0.1% |
| Q3 FY2024 | Sep 30, 2024 | $1.20B | +0.1% |
| Q2 FY2024 | Jun 30, 2024 | $1.20B | +0.1% |
| Q1 FY2024 | Mar 31, 2024 | $1.20B | +0.1% |
| Q4 FY2023 | Dec 31, 2023 | $1.20B | +0.1% |
| Q3 FY2023 | Sep 30, 2023 | $1.20B | +0.1% |
| Q2 FY2023 | Jun 30, 2023 | $1.20B | +0.1% |
| Q1 FY2023 | Mar 31, 2023 | $1.20B | +0.1% |
| Q4 FY2022 | Dec 31, 2022 | $1.20B | +11291.5% |
| Q3 FY2022 | Sep 30, 2022 | $1.20B | +11147.3% |
| Q2 FY2022 | Jun 30, 2022 | $1.20B | +11004.4% |
| Q1 FY2022 | Mar 31, 2022 | $1.20B | +10878.2% |
| Q4 FY2021 | Dec 31, 2021 | $10.51M | -14.2% |
| Q3 FY2021 | Sep 30, 2021 | $10.65M | -13.0% |
| Q2 FY2021 | Jun 30, 2021 | $10.78M | -11.9% |
| Q1 FY2021 | Mar 31, 2021 | $10.90M | -10.7% |
| Q4 FY2020 | Dec 31, 2020 | $12.26M | -9.7% |
| Q3 FY2020 | Sep 30, 2020 | $12.24M | -97.2% |
| Q2 FY2020 | Jun 30, 2020 | $12.23M | -97.2% |
| Q1 FY2020 | Mar 31, 2020 | $12.21M | -97.2% |
| Q4 FY2019 | Dec 31, 2019 | $13.58M | -96.9% |
| Q3 FY2019 | Sep 30, 2019 | $437.81M | -0.2% |
| Q2 FY2019 | Jun 30, 2019 | $437.68M | -0.2% |
| Q1 FY2019 | Mar 31, 2019 | $437.61M | +0.7% |
| Q4 FY2018 | Dec 31, 2018 | $438.94M | +1.0% |
| Q3 FY2018 | Sep 30, 2018 | $438.80M | +1.0% |
| Q2 FY2018 | Jun 30, 2018 | $438.78M | +1.0% |
| Q1 FY2018 | Mar 31, 2018 | $434.68M | +0.1% |
| Q4 FY2017 | Dec 31, 2017 | $434.58M | +0.1% |
| Q3 FY2017 | Sep 30, 2017 | $434.48M | – |
| Q2 FY2017 | Jun 30, 2017 | $434.39M | – |
| Q1 FY2017 | Mar 31, 2017 | $434.29M | – |
| Q4 FY2016 | Dec 31, 2016 | $434.19M | – |
See a number that looks wrong?